Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis
<p dir="ltr">Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas’ tremendous variability in tumor behavior and slow...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513534551916544 |
|---|---|
| author | Reem Halabi (22482097) |
| author2 | Fatima Dakroub (13014998) Mohammad Z. Haider (5429717) Stuti Patel (3899836) Nayef A. Amhaz (22482098) Mohammad A. Reslan (22482102) Ali H. Eid (5461829) Yehia Mechref (17849097) Nadine Darwiche (12223496) Firas Kobeissy (17849094) Ibrahim Omeis (11496641) Abdullah Shaito (20545181) |
| author2_role | author author author author author author author author author author author |
| author_facet | Reem Halabi (22482097) Fatima Dakroub (13014998) Mohammad Z. Haider (5429717) Stuti Patel (3899836) Nayef A. Amhaz (22482098) Mohammad A. Reslan (22482102) Ali H. Eid (5461829) Yehia Mechref (17849097) Nadine Darwiche (12223496) Firas Kobeissy (17849094) Ibrahim Omeis (11496641) Abdullah Shaito (20545181) |
| author_role | author |
| dc.creator.none.fl_str_mv | Reem Halabi (22482097) Fatima Dakroub (13014998) Mohammad Z. Haider (5429717) Stuti Patel (3899836) Nayef A. Amhaz (22482098) Mohammad A. Reslan (22482102) Ali H. Eid (5461829) Yehia Mechref (17849097) Nadine Darwiche (12223496) Firas Kobeissy (17849094) Ibrahim Omeis (11496641) Abdullah Shaito (20545181) |
| dc.date.none.fl_str_mv | 2023-11-09T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/cancers15225339 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Unveiling_a_Biomarker_Signature_of_Meningioma_The_Need_for_a_Panel_of_Genomic_Epigenetic_Proteomic_and_RNA_Biomarkers_to_Advance_Diagnosis_and_Prognosis/30415147 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Biochemistry and cell biology Genetics Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Oncology and carcinogenesis meningioma NF2 mutations biomarker miRNA proteomics |
| dc.title.none.fl_str_mv | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas’ tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningiomas, with a focus on neurofibromatosis type 2 (<i>NF2</i>) and non-<i>NF2</i> mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, metabolomics-, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in pre-operative and post-operative decision making. Discovery of novel biomarkers will allow, in combination with WHO grading, more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancers<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://doi.org/10.3390/cancers15225339" target="_blank">https://doi.org/10.3390/cancers15225339</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a39559b31ef6fc115fa32d0157c5848c |
| identifier_str_mv | 10.3390/cancers15225339 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30415147 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and PrognosisReem Halabi (22482097)Fatima Dakroub (13014998)Mohammad Z. Haider (5429717)Stuti Patel (3899836)Nayef A. Amhaz (22482098)Mohammad A. Reslan (22482102)Ali H. Eid (5461829)Yehia Mechref (17849097)Nadine Darwiche (12223496)Firas Kobeissy (17849094)Ibrahim Omeis (11496641)Abdullah Shaito (20545181)Biological sciencesBiochemistry and cell biologyGeneticsBiomedical and clinical sciencesMedical biochemistry and metabolomicsNeurosciencesOncology and carcinogenesismeningiomaNF2 mutationsbiomarkermiRNAproteomics<p dir="ltr">Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas’ tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningiomas, with a focus on neurofibromatosis type 2 (<i>NF2</i>) and non-<i>NF2</i> mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, metabolomics-, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in pre-operative and post-operative decision making. Discovery of novel biomarkers will allow, in combination with WHO grading, more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes.</p><h2>Other Information</h2><p dir="ltr">Published in: Cancers<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://doi.org/10.3390/cancers15225339" target="_blank">https://doi.org/10.3390/cancers15225339</a></p>2023-11-09T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/cancers15225339https://figshare.com/articles/journal_contribution/Unveiling_a_Biomarker_Signature_of_Meningioma_The_Need_for_a_Panel_of_Genomic_Epigenetic_Proteomic_and_RNA_Biomarkers_to_Advance_Diagnosis_and_Prognosis/30415147CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304151472023-11-09T06:00:00Z |
| spellingShingle | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis Reem Halabi (22482097) Biological sciences Biochemistry and cell biology Genetics Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Oncology and carcinogenesis meningioma NF2 mutations biomarker miRNA proteomics |
| status_str | publishedVersion |
| title | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis |
| title_full | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis |
| title_fullStr | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis |
| title_full_unstemmed | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis |
| title_short | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis |
| title_sort | Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis |
| topic | Biological sciences Biochemistry and cell biology Genetics Biomedical and clinical sciences Medical biochemistry and metabolomics Neurosciences Oncology and carcinogenesis meningioma NF2 mutations biomarker miRNA proteomics |